Celldex Reports Preliminary Cohort Data From Pilot Study Of CDX-301

(RTTNews) - Celldex Therapeutics, Inc. (CLDX) reported new clinical data on CDX-301, or recombinant human Flt3 ligand, a potent hematopoietic cytokine. The early data were presented at the 2016 BMT Tandem Meeting,

"CDX-301 shows a favorable safety profile and effectively mobilizes early stem cells when used alone, and we expect even greater yields in the next cohort where we combine with Mozobil," said Thomas Davis, EVP and Chief Medical Officer of Celldex.

Celldex believes CDX-301 may hold significant opportunity for synergistic development in combination with other proprietary molecules in the company's portfolio and in external development.